Substitute for FORM 1449A/B/PTO	Complete	if Known
	Application Number:	10/573,166
INFORMATION DISCLOSURE	Filing Date:	March 21, 2006
INFORMATION DISCLOSURE	First Named Inventor:	Akito TANAKA
STATEMENT BY APPLICANT	Group Art Unit:	Unassigned
	Confirmation Number:	4595
(Use as many sheets as necessary)	Examiner Name:	Unassigned
Sheet 1 of 1	Attorney Docket Number:	43512-104182

				U.S. PATENT DOCUMENTS		·
	U.S. Patent Document			•		
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	AA	3,654,349		Shen et al.	Apr. 4, 1972	
	AB	3,692,651		Sletzinger et al.	Sep. 19, 1972	
	AC	5,466,823		Talley et al.	Nov. 14, 1995	
	AD	5,756,529		Isakson et al.	May 26, 1998	
	AE	6,200,771		Liu et al.	mr. 13, 2001	
	AF	6,500,610		Pamukcu et al.	Dec. 31, 2002	
						<u> </u>
						ļ
		1				

FOREIGN PATENT DOCUMENTS								
	Foreign Patent Document			nt			Tran	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
	AG	JP	53-12512		Merck & Co., Inc.	May 1, 1978		X+
	AH	JP	57-27107		Merck & Co., Inc.	Jun. 8, 1982		X+
	AI	JP	9-506350		G.D. Searle & Co.	Jun. 24, 1997	T	X+
	AJ	JP	11-94823		Cell Pathway, Inc.	Apr. 9, 1999	T	X+
_	AK	JP	11-514991		G.D. Searle & Co.	Dec. 21, 1999		X+
	AL	JP	2000-186047		Cell Pathway, Inc. 7 4 2000	-Ju. 4, 2000 -		X+
	<u> </u>	 		_			-	

11/12

	OTHER - NON PATENT LITERATURE DOCUMENTS							
Examiner	Doc	linclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		Translation				
Initials	No.			No*+				
								
				L				

CHDS01 CLARCHER 371328vI

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.H./

EXAMINER	/Sheela Huff/	DATE CONSIDERED	10/14/2008

^{*}A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).